title: Alcohol-induced pancreatic injury.
abstract: Alcoholic pancreatitis is a major complication of alcohol abuse. Until recently, it was generally accepted that alcoholic pancreatitis was a chronic disease from the outset. However, evidence is now emerging in support of the 'necrosis-fibrosis' hypothesis that alcoholic pancreatitis begins as an acute process and that repeated episodes of acute injury lead to the changes of chronic pancreatitis (acinar atrophy and fibrosis) resulting in exocrine and endocrine dysfunction. The treatment of acute pancreatitis follows the regimen of bed rest, nasogastric suction, analgesia and intravenous support. The role of additional therapeutic measures such as prophylactic antibiotics, antioxidants and enteral nutrition in severe cases has not yet been precisely defined. The treatment of chronic pancreatitis involves attention to its three cardinal features: pain, maldigestion and diabetes. With respect to the pathogenesis of alcoholic pancreatitis, the focus of research over the past 30 years has shifted from the sphincter of Oddi and ductular abnormalities to the acinar cell itself. It has now been established that the acinar cell is capable of metabolizing alcohol and that direct toxic effects of alcohol and/or its metabolites on acinar cells may predispose the gland to injury in the presence of an appropriate trigger factor. A significant recent development relates to the characterization of pancreatic stellate cells, increasingly implicated in alcoholic pancreatic fibrosis. This chapter summarizes the natural history, clinical features, current trends in treatment as well as recent advances in our understanding of the pathogenesis of alcoholic pancreatitis.
authors.affiliation: Pancreatic Research Group, Department of Gastroenterology, Bankstown-Lidcombe, Australia.
authors.forename: M V
authors.initials: MV
authors.lastname: Apte
authors.forename: J S
authors.initials: JS
authors.lastname: Wilson
mesh_terms: D000208:Acute Disease; D000437:Alcoholism / Q000150:complications*; D000818:Animals; D002908:Chronic Disease; D003920:Diabetes Mellitus / Q000209:etiology / Q000628:therapy; D000431:Ethanol / Q000633:toxicity*; D005355:Fibrosis; D020022:Genetic Predisposition to Disease; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D008286:Malabsorption Syndromes / Q000209:etiology / Q000628:therapy; D010146:Pain / Q000209:etiology; D059408:Pain Management; D010179:Pancreas / Q000166:cytology / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D019512:Pancreatitis, Alcoholic / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology / Q000628:therapy*
chemical_list: D018836:Inflammation Mediators; D000431:Ethanol